Amrut Medhekar to exit Akums Drugs and Pharma as CEO-CDMO Business

New Delhi:  Akums Drugs and Pharma has announced the resignation of Amrut Medhekar, CEO- CDMO Business of the Company effective July 15 to pursue new opportunities and challenges.

“In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held on 26th May, 2025 has accepted resignation of Mr. Amrut Medhekar, CEO (CDMO) of the Company w.e.f 15.07.2025,” AKums stated in a BSE filing.

He is a seasoned business leader with 28+ years of versatile experience spanning General Management, Sales, Marketing, and Functional Leadership in the pharmaceutical industry.

Before joining Akums, Medhekar held the position of President, India Business at Wockhardt. He also spent over 13 years at Zydus Group, where he successfully led Acute as well as Chronic therapy business clusters– Antibiotics, Gastroenterology, Cardiology & Diabetes, Orthopedics, Rheumatology, Ophthalmology, Nutrition etc. He also led critical functions as – Commercial Excellence/ Strategy, SFE, Portfolio & Business Development, Marketing excellence & Digital, Business Insights & Key account/ Institution business, Nepal Business.

Medhekar’s earlier roles included leadership positions at Ranbaxy, Torrent Pharmaceuticals, LifeMedicare Biotech, Novartis, and even outside the pharma space at JK Tyre & Industries Ltd.

Read also: Akum Drugs Gets CDSCO Panel Nod To Conduct Post Marketing Surveillance study of Linezolid Sustained Release Tablets

Akums Drugs & Pharmaceuticals Ltd. is a contract-manufacturing pharmaceutical company of India. The organization deals in the manufacturing and export of formulations in a wide spectrum of dosage forms & therapeutic segments. The company is currently supplying to almost all Indian and multinational pharmaceutical companies across the globe. The 10 state-of-the-art facilities are dedicated to oral solid dosage forms (with separate units for beta lactum and non-beta lactum formulations), Oral liquid dosage forms, Sterile dosage forms (Injectable, eye, ear & nasal), hormonal (oral and injectable), Ointments & cosmetics, Ayurvedic, food supplements & nutraceuticals and animal health care.

The organization is certified with WHO-GMP, ISO 9001 : 2008, ISO 14001:2004 certificates and various international accreditations, like; ANVISA, Brazil, NAFDAC, Nigeria, FDB, Ghana, PMPB, Malawi amongst others.

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March